References
- Duclos P. National Immunization Technical Advisory Groups (NITAGs): guidance for their establishment and strengthening. Vaccine 2010;28(Suppl 1):A18-25
- Ismail SJ, Langley JM, Harris TM, et al. Canada’s National Advisory Committee on Immunization (NACI): evidence-based decision-making on vaccines and immunization. Vaccine 2010;28(Suppl 1):A58-63
- Sibbald B. One country, 13 immunization programs. CMAJ 2003;168:598
- Freed GL. The structure and function of immunization advisory committees in Western Europe. Hum Vaccin 2008;4:292-7
- Public Health Agency of Canada GoC. National Immunization Strategy (NIS). Government of Canada; 2010
- Public Health Agency of Canada GoC. Canadian National Report on Immunization, 2006. CCDR; Caanda: 2006. 32S3: p. 1-44
- Erickson LJ, De Wals P, Farand L. An analytical framework for immunization programs in Canada. Vaccine 2005;23:2470-6
- Public Health Agency of Canada Government of Canada. Interim evaluation of the National immunization strategy April 2003 to June 2007. Government of Canada; Ottawa: 2008
- Macdonald N, Bortolussi R. A harmonized immunization schedule for Canada: a call to action. Paediatr Child Health 2011;16:29-31
- Scheifele DW, Ward BJ, Halperin SA, et al. Approved but non-funded vaccines: accessing individual protection. Vaccine 2014;32:766-70
- Black S. The role of health economic analyses in vaccine decision making. Vaccine 2013;31:6046-9
- Immunization Vaccines and Biologicals, World Health Organization. Global immunization vision and strategy. UNICEF; Geneva: 2011
- Smith JC. The structure, role, and procedures of the U.S. Advisory Committee on Immunization Practices (ACIP). Vaccine 2010;28(Suppl 1):A68-75
- Hall AJ. The United Kingdom Joint Committee on Vaccination and Immunisation. Vaccine 2010;28(Suppl 1):A54-7
- Nolan TM. The Australian model of immunization advice and vaccine funding. Vaccine 2010;28(Suppl 1):A76-83
- Hartz S, John J. Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review. Int J Technol Assess Health Care 2008;24:465-72
- Golec JH, Vernon JA. European pharmaceutical price regulation, firm profitability, and R&D spending, NBER working paper No. 12676. National Bureau of Economic Research; Cambridge MA: 2006
- Tsoi B, Masucci L, Campbell K, et al. Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences. Expert Rev Pharmacoecon Outcomes Res 2013;13:497-511
- Philipson TJ, Jena AB. Striking a balance on new technology. cost-effectiveness analysis can help sort out emerging health care technologies, but what are the consequences for continued medical innovation? AHIP Cover 2006;47:29-31-3
- Drummond M, Brown R, Fendrick AM, et al. Use of pharmacoeconomics information – report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 2003;6:407-16
- Johnson AP, Sikich NJ, Evans G, et al. Health technology assessment: a comprehensive framework for evidence-based recommendations in Ontario. Int J Technol Assess Health Care 2009;25:141-50
- (CADTH). Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies. CADTH; Ottawa:Canada: 2006
- Organization for Economic Cooperation and Development (OECD). Health Technologies and Decision Making. OECD; Paris: 2005. p. 160
- Culyer AJ. Deliberative processes in decisions about health care technologies: combining different types of evidence, values, algorithms and people. 2009
- Giesecke J. Modern infectious disease epidemiology. Second edition. London: Arnold, a member of the Hodder Headline group, 2002.
- Jacobs P, Yim R, Ohinmaa A, Varney J. Economics of childhood immunizations in Canada: data book. Institute of Health Economics; Edmonton, Alberta
- Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003;23:76-82
- Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 2010;28:2356-9
- Pitman R, Fisman D, Zaric GS, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5. Med Decis Making 2012;32:712-21
- Karnon J, Stahl J, Brennan A, et al. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force – 4. Value Health 2012;15:821-7
- Macal CM, North MH. Tutorial on agent-based modelling and simulation. J Simulation 2010;4:151-62
- Edwards RT, Charles JM, Lloyd-Williams H. Public health economics: a systematic review of guidance for the economic evaluation of public health interventions and discussion of key methodological issues. BMC Public Health 2013;13:1001
- Isabelle W, Duclos P. Editorial The Health Policy and Institutional Development Unit of AMP is WHO Collaborating Centre for evidence-informed immunization policymaking. 2013. Available from: www.sivacinitiative.org
- National Advisory Committee on Immunization (NACI). Evidence-based recommendations for immunization – methods of the National Advisory Committee on Immunization. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2009;35:1-10